Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent

MELBOURNE, Australia and SAN DIEGO, Dec. 13, 2023 /PRNewswire/ -- Imagion Biosystems Limited (ASX: IBX) recently announced positive results following completion of the IBI10103 phase I clinical trial evaluating the safety and clinical feasibility ofMagSense® HER2 Imaging Agent (MSH2IA) as an adju...